The holiday season approaches, so here’s a quick look at the year that was for Indian Pharma, before we disappear into a haze of year-end festivities. It’s a mixed bag (what year isn’t?) including stuff that could influence the way things work in the years ahead. For convenience, I’ve divided up what I think are … Continue reading India #Pharma 2014 : A quick look back. Part Three #pricing #nppa
Tag: drug pricing
India’s logic-defying drug pricing moves : My column in Quartz India
Just when I thought things were getting a bit dull, they go and do this.
Indian #pharma policy : Missing the wood for the trees
The latest round of price interventions imposed on the drug industry by India's National Pharmaceutical Pricing Authority (NPPA) has the industry fulminating. Just when it was recovering from being all but snubbed in the Union Budget, it finds that the NPPA has quietly pulled the rug from under its feet leaving it sprawled on the … Continue reading Indian #pharma policy : Missing the wood for the trees
Think deeper about drugs affordability : my column in the Indian Express
My latest column in The Indian Express addresses the question of drug affordability. In this column, I have argued that the new Drug Price Control Order (DPCO), soon to complete a year in existence, while a major preoccupation with mandarins and managers alike in the last few months, is not a panacea for affordability. I … Continue reading Think deeper about drugs affordability : my column in the Indian Express
India & drug pricing : Now, list of essential meds questioned
In continuation of the challenges arising from the roll-out of India's new drug pricing policy, a question has now been raised on the current National List of Essential Medicines (NLEM) that specifies the universe of drugs under price control. "Some may argue that the NLEM is not appropriately designed," said Dilsher Singh Kalha, Secretary, Department … Continue reading India & drug pricing : Now, list of essential meds questioned
India’s new drug pricing policy : will data be the stumbling block?
On December 7, India's National Pharmaceutical Pricing Policy 2012 was finally tabled in Parliament. Assuming that this policy does get rolled out irrespective of a Supreme Court hearing on drug pricing playing out in parallel, the cornerstone of the policy i.e.data may create some vexing issues. The Policy envisages fixing ceiling prices of specified strengths … Continue reading India’s new drug pricing policy : will data be the stumbling block?
FDI in pharma : another punch
The issue of controlling foreign direct investment (FDI) in the Indian pharmaceutical sector continues to make headlines with various arms of the government putting forth their own formulas to tame the grasping foreign hand. The Indian Express reports that the ministry of commerce under Anand Sharma would like all FDI proposals - including where foreign … Continue reading FDI in pharma : another punch
Think different : Big Pharma and drug pricing in emerging markets
I'd like to introduce a guest column by Salil Kallianpur, a healthcare marketing professional with experience in the pharmaceutical and medical devices industries. Salil is an avid reader and follower of healthcare current affairs, its politics, and strategies. He comments on the intersection of healthcare and life on his blog My Pharma Reviews. He is … Continue reading Think different : Big Pharma and drug pricing in emerging markets
Drug price controls growing popular?
Bloomberg reports that Germany will soon levy over $2bn worth of price cuts on drug makers launching new products. Germany is the world's third biggest pharma market after the US and Japan, it points out. "The law, backed by the lower house today, gives companies a one-year window to negotiate prices with insurers after introducing … Continue reading Drug price controls growing popular?
Apothecurry 